3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Conditions
Papillomavirus Infections
2
Leiomyoma
2
Inflammation
2
Frailty
2
Uterine Cervical Dysplasia
1
Squamous Intraepithelial Lesions
1
Radiodermatitis
1
Liver Neoplasms
1
Liver Cirrhosis
1
Fibrosis
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Atypical Squamous Cells of the Cervix
1
Interventions
epigallocatechin gallate
2
Ascorbic Acid
2
semaglutide
1
salicylsalicylic acid
1
microcrystalline cellulose
1
dapagliflozin
1
cytisine
1
bupropion hydrochloride, naltrexone hydrochoride drug combination
1
XENP 1595
1
Vitamin D
1
Topiramate
1
Tirzepatide
1
Tablets
1
Spirometry
1
Specimen Handling
1
Sodium Salicylate
1
Selenium
1
Saline Solution
1
Resistance Training
1
Reperfusion
1
Qsymia
1
Probiotics
1
Pregabalin
1
Platelet Count
1
Plastic Surgery Procedures
1
Phentermine
1
Omeprazole
1
Naltrexone
1
Losartan
1
Liraglutide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Inflammation
×
epigallocatechin gallate
×
1 year
×
Clear all
NCT04553666
2026-05-07
ReFOCUS1
University of Rochester
Phase 2
Completed
24 enrolled
17 charts
NCT06068543
2026-03-06
ReFOCUS2
University of Rochester
Phase 2
Recruiting
118 enrolled